Objectives: To evaluate the 9-month safety and efficacy of polymer-free sirolimus eluting drug eluting stents in septuagenarians and octogenarians.
by morphologically more difficult lesions and higher rates of target lesion revascularization (TLR) and mortality. 3 In particular peri-interventional mortality in this octogenarian patient population can be in the 7-8% range in case of acute coronary syndrome (ACS). 4 When treating older patients, the interventionalist is plagued by balancing the risk-to-benefit ratio of drug-eluting stent (DES) implantations which require dual antiplatelet therapy (DAPT) between 6 and 12 months 5 depending on and the increased risk of bleeding and stent thrombosis (ST). 3 To untie this Gordian knot of choosing the proper revascularization strategy while managing the risks of bleeding and ST, and to achieve acceptably low TLR rates, may be facilitated with the new generation of polymerfree DES. One potential candidate to resolve this dilemma is the use of polymer-free sirolimus/probucol DES which was previously compared to a zotarolimus-eluting stent in a large randomized trial 6 with a longterm follow-up of 5 years 7 and subgroup analysis in diabetics 8 and patients with ST elevation infarction. 9 We report the results of a previously published large all-comers population 10 registry with a focus on septuagenarian and octogenarian subgroups.
2 | METHODS
| Study population, end points, and definitions
On the basis of the international ISAR 2000 all-comers registry population 10 (ClinicalTrials.gov Identifier NCT02629575) a post-hoc subgroup analysis was conducted in three age groups, that is, <70 years, septuagenarians (≥70 years, <80 years), and in octogenarians (≥80 years).
The primary end point was TLR at 9 months. Secondary end points were the 9-month major adverse cardiac event (MACE) rate, the in-hospital MACE rate, and the corresponding rates of myocardial infarction (MI) and peri-procedural mortality. Furthermore, the acute/ subacute ST rate was determined as defined by the ARC criteria. 11 The BARC scale was used in our assessment to determine the severity of bleeding episodes.
12
A glomerular filtration rate (GFR) <30 mL/min/1.73 m 2 was the limit to define end stage renal disease with a cut-off GFR rate for mandatory dialysis of <15 mL/min/1.73 m. 2 Severely tortuous vessels were defined with angulations >45°.
| Inclusion and exclusion criteria
Due to the all-comers character of this study, patients ≥18 years of age with stable angina and objective proof of ischemia or patients with ACS had to meet the requirements for PCI. 13 De novo or restenotic lesions with reference diameters from 2.0 to 4.0 mm could be treated in single or multiple vessels.
| Procedures and medication
Femoral or radial vascular access was admissible with recommended introducer sheaths of at least five French. Either direct stenting or pre-dilatation with a balloon catheter of any given preference were allowed by the study protocol. According to the institutional guidelines of the cardiac center, intravenous heparin (70 IU/kg) was given in all patients and supplemented when required. 
| Data collection and ethics
An established data capture system with a proven track record 14 was used which allowed for plausibility checks during all stages of data entry. Data quality issues were handled on a national level through dedicated contacts to the corresponding study nurses in each cardiac center. Follow-up time windows were closely monitored and automatic email alerts were sent to the corresponding study nurse.
All ethics votes prior to patient recruitment for both study cohorts 
| Statistics
The significance level α of 0.05 was used for all tests. The two-sided
Fisher's exact test or the Chi 2 statistic were used whenever applicable for dichotomous variables, whereas continuous variables were compared with the unpaired t-test or the Mann-Whitney U-test in case the Shapiro-Wilk test revealed a strong deviation from a normal distribution. Kaplan-Meier survival analyses were conducted based on the log-rank test. SPSS version 24.0 (IBM, Munich, Germany) was used for all statistical analyses whereas biometric estimates for the previously conducted unselected patient cohorts were calculated with nQuery/ nTerim version 2.0 (Statistical Solutions Ltd. Cork, Ireland).
3 | RESULTS
| Patients
As reported elsewhere 10 a total of 2877 patients were recruited in the Coroflex ISAR 2000 registry. Significant differences for male KHERAD ET AL.
| 339 gender (P < 0.001), hypertension (P < 0.001), and the rates of STEMI/NSTEMI (P < 0.001) were observed across age groups (Table 1 ). The rate of older patients was higher in Europe, for example, octogenarian patients amounted to 15.1% of all patients treated in Europe versus only 7.6% in Asia. In contrast, in patients of less than 70 years of age the corresponding rates were 50.6% versus 68.3% (P group < 0.001).
| Lesions, procedures, and co-medication
The distributions of treated vessels are different across age groups.
Noteworthy is the higher rate of lesions in the left anterior descending (LAD) coronary artery in octogenarians (P group = 0.009). In addition, except for the rates of chronic total occlusions, bifurcations and the rate of AHA/ACC type B2/C type lesions; all other lesion morphological characteristics were significantly different across age groups (Table 2) . Pre-dilatation (Table 2 ) was more frequently done in older patients (44.3% vs 37.7% vs 35.6%, P = 0.004) and higher inflation pressures were applied in older patients as well (14.4 atm vs 14.1 atm vs 13.8 atm, P = 0.003).
Preferred peri-procedural antiplatelet agents (Table 3) in octogenarians were primarily clopidogrel (59.8%) and prasugrel (15.3%). Oral anti-coagulants were more frequently prescribed in octogenarians and septuagenarians as compared to the age group <70 years (2.7% vs 2.9% vs 0.7%, P = 0.003). Dual anti-platelet therapy duration (Table 4) was shortest in the octogenarian subgroup as compared to the younger age groups (9.5 ± 3.2 months vs 9.8 ± 2.9 months vs 10.5 ± 2.5 months, P < 0.0001). Triple therapy (Table 3) was prescribed in 2.9%
(septuagenarians) and 2.7% (octogenarians) which was almost threefold as high as the corresponding rate in the younger age group
(1.1%, P group = 0.003).
| Clinical outcomes
The primary endpoint TLR (Table 5 ) at 9 months was 3.1%
(10/320) in octogenarians, 3.0% (24/789) in septuagenarians, and 1.7% (24/1404) in patients <70 years of age. Despite no differences in terms of TLR across the age groups (P = 0.080), the 9-month accumulated MACE rate (Figure 1 , log-rank P < 0.001) was the highest in octogenarians 7.2% (23/320) mostly driven by increased overall mortality 4.4% (14/320). Bleeding occurred more frequently in octogenarians as compared to the younger age groups (4.6% vs 2.7% vs 1.9%, P = 0.012) whereas there was no difference in the rates of ST (P = 0.970). In particular, BARC 2-5 bleeding episodes were more frequent in octogenarians as compared to the younger age groups (2.7% vs 0.6% vs 0.6%, P < 0.001).
In patients who were on triple therapy, we found a 2.0%
(1/50) 9-month MACE rate with six patients who had bleeding complications (BARC 1: 4/6, BARC 2: 2/6). These were numerically higher in the older age groups, that is, 28.6% (2/7 in octogenarians), 15.4% (4/26, septuagenarians), and 0.0%
(0/17, <70 years).
| DISCUSSION
To our knowledge this is the largest study in an octogenarian all-comer population treated with a polymer-free DES technology. Albeit the fact that previously detected cardiovascular risk factors and lesion morphological characteristics such as the previously reported higher rates of LAD stenting in octogenarians 3 were confirmed in our series; some outcomes of this study have not been reported to our knowledge. 
| Target lesion revascularization
First of all, we could not detect a difference in TLR across our age groups (P = 0.080). Yazji et al 3 reported a 12-month TLR rate of 3.7% which was higher as compared to patients <80 years of age (P = 0.005). Our 9-month TLR rate was in the same range (3.1%), however, this rate was not different from the TLR rate in the 70-79 year age group (3.0%). This finding may have been favored by a lack of power, nonetheless, the accumulated ST rates were all quite similar (P = 0.970) across age groups, that is, 0.7% (<70 years), 0.6% (septuagenarians), and 0.6% (octogenarians). This finding has to be evaluated together with the DAPT duration which was significantly longer in the octogenarian subgroup.
Taken together, this may suggest that the polymer-free DES we used in this study can be safely used with low ST rates and acceptably low TLR and MACE rates. In addition, bleeding episodes were more frequent in octogenarians which is in agreement with the current literature. rates for patients 80 years and older in the 12-15% range which is also substantially higher as compared to our outcomes. In this context one needs to be prudent to draw quick conclusions since confirmed ST events may be more difficult to obtain in older patients unless revascularizations can be done in due time.
Most patients who passed away prematurely had BARC 1 bleeding episodes while severe bleeding (BARC ≥ 3) occurred in relatively small subgroups. However, in octogenarians who passed away, there were two BARC 3a episodes versus none in the younger subgroups (14.3% vs 0.0% vs 0.0%). As previously mentioned, the use of anti-coagulants was more frequent in older patients.
Therefore, it can be suspected that the higher bleeding rates are more likely to be an outcome of the increased use of anti-coagulants which is not primarily related to age.
| Antiplatelet and triple therapy
We found that prasugrel usage amounted to 15.3% in the octogenarian subgroup despite the fact that this thienopyridine has an age cut-off of 75 years. However, we suspect that prasugrel was given in 5 mg per day dosages in some centers despite the established indications specified by the drug manufacturer.
There were 54 patients who were on triple therapy. Of these, there were 50 patients with 9-month follow-up. The corresponding MACE rate was low (2.0%), nevertheless, older patients in this subgroup had more bleeding events. In triple therapy patients older than 70 years, the bleeding rate in this study was in the 15-28% range versus 0.0% in the sub-septuagenarian age group. This, however, is also in agreement with recent findings by Bavishi et al 17 who
conducted a meta-analysis of observational studies. 
| Study limitations
The findings in this study provide guidance, however, the statistical basis is descriptive in nature. Randomized controlled trials or propensity score matching, even though desirable, would be extremely challenging to conduct so that bias introducing factors can be eliminated. More data on other demographic risk factors such as the smoking status would have been desirable as well but
were not assessed to facilitate data entry. Unfortunately, we did not a priori assess the vascular access site (femoral vs radial) which would have been very helpful to discuss bleeding events in the BARC 2 category.
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